A heart is the most important organ we have in our bodies. At the same time, it is very vulnerable. Many diseases have a disastrous impact on the heart—it becomes stiff and less functional. To prevent its failure, researchers are working on a new medicine for cardiac disease.
Heart failure is a dangerous, progressive cardiac illness. Each year, 670 000 people are diagnosed with this condition. Cardiovascular issues account for 34 percent of all deaths in the world. That is why there is an urgent necessity in the drugs that can help treat this condition.
A company in Nevada plans to develop a cardiac treatment using marijuana compounds. The base for the treatment is a novel therapy patented in 2015 by a researcher from the University of Hawaii. Dr. Alexander Stokes explains the science behind the therapy. It is based on the regulation of the receptor TRPV1 that is involved in the progression to heart failure. According to the researchers, the receptor can be regulated by plant-based cannabinoids. Both psychoactive and non-psychoactive compounds of marijuana have medicinal properties, and they exert them by binding to receptor proteins in the cell membranes.
Previously, the license for the therapy belonged to Makai Biotechnology LLC. However, last December, it was obtained by a company named GrowBlox Life Sciences LLC that belongs to GB Sciences Inc. The latter provides an impressive portfolio of proprietary mixtures that have great prospects in regulating the TRPV1 receptor.
It is also a major step for GB Sciences Inc. In addition to the creation of a new medicine, they have a chance to study non-classical cannabinoid receptors and the drugs that interact with them. Dr. Andrea Small-Howard, Chief Science Officer of GB Sciences, claims that the “cannabis-plant-based approach may provide additional clinical benefits to patients due to the 'entourage effect.'” It means that some plant's compounds work better in combination with other cannabinoids than when given alone. In general, cannabinoids in native extracts are more successful in the regulation of the TRPV1 receptor than purified cannabinoids. Besides, unlike the case with many other drugs, the side effects of the plant-based therapies are well-tolerated.
John Pross, the CEO of the company, mentions that Dr. Small-Howard's team, which will work on the therapy, is leading GB Sciences to successful drug discovery. Their efforts will save millions of people from cardiac disease. The company is very proud of the team and its leader.